Clinical Trial Update: Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus® [NA]

View source ↗

Summary

This clinical trial update describes a pharmacokinetic bioequivalence study comparing Nebcinal inhalation therapy to Tobi in cystic fibrosis patients, using Aer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Nebcinal
• TOBI (Tobramycin inhalation solution)

Snippet

Sponsor: Erempharma | Conditions: Cystic Fibrosis | NA | Status: UNKNOWN